Pharmacolog Appoints New Development Manager

Pharmacolog appoints Jörgen Höjdmo as the new Development Manager. Jörgen has extensive experience in leading advanced development projects and is one of the main architects of the company’s current DrugLog® systems.

As a development manager Jörgen will be responsible for the company’s product development and manage internal and external resources. Jörgen Höjdmo has a MSc in Engineering Physics and more than 20 years of experience in technology and software development. He has also worked as CEO of Digital Diary AB, which later was sold to FormPipe AB 2005 where Jorgen continued to work as a Partner Manager until 2007. The last 10 years has Jörgen mainly worked as a consultant in management and advanced technology development and lead for 6 years an extensive project for the Swedish Armed Forces. Jörgen has since 2008 also been involved in Pharmacolog development of DrugLog®.

CEO Mats Högberg commented. “We are very pleased that Jorgen decided to accept the role as development manager. As we are starting new exciting development projects, it is essential that we have someone with the experience and technical expertise to lead our team. Jörgen’s unique competence in analytic technology combined with experience in managing development projects will mean a lot for our ability to quickly realize new innovations within our vision of individualized care and optimized drug use. ”

Read the official press release (Swedish) here: Pharmacolog tillsätter ny utvecklingschef.

Extended collaboration with Uppsala University regarding dosage of antibiotics

Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.

The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.

Hans Dahlin, Research Director and Founder, comments: R...

Study in Lille completed

The study conducted at the University Hospital in Lille with DrugLog in order to control drug preparations carried out in the operating room has now been completed. A total of 22 different drugs were checked and the result indicated an error rate in the drug preparations of 6.9%.

The study, conducted during the summer, was part of a doctoral thesis and the results were presented in connection with the dissertation at the Pharmacy Department earlier this fall. Of the 232 analyzes analyzed, it was found that 6.9% had a concentration beyond the tolerance level. According to the study, the cost of an error medication is about 4,000 €, which means that DrugLog control in these cases potentially result...

DrugLog® will be evaluated by a hospital chain in New York

Pharmacolog and one of New York’s most reputable hospital chains have signed an agreement that DrugLog® should be evaluated at two of the organization’s hospitals for use in a Drug Diversion program. The hospital chain pays for the evaluation scheduled to start in December and is expected to be completed in the first quarter of 2018.

Theft of narcotic intravenous drugs in healthcare is an growing problem. In the US, the authorities have initiated various preventive actions as the abuse of opiates reaches alarming levels. Since DrugLog can identify such drugs and also see if they have been manipulated in any way, DrugLog is a useful tool to prevent this development. The interest in usi...

Nyemissionen registrerad

Pharmacolog i Uppsala AB (publ) har genomfört en nyemission med företrädesrätt för befintliga aktieägare med teckningstid 27 september – 13 oktober 2017 efter beslut av styrelsen den 28 augusti med stöd av bemyndigande från Bolagets årsstämma den 3 maj 2017. Emissionen, som övertecknades, tillförde Bolaget 19,6 MSEK före emissionskostnader.

Emissionen har registrerats av Bolagsverket den 1 november 2017. I samband med att emissionen har registrerats av Bolagsverket kommer betalda tecknade aktier (BTA) att avregistreras och ersättas av nya aktier. Sista dag för handel med BTA på Aktietorget är den 6 november 2017.

Genom nyemissionen har aktiekapitalet i Pharmacolog ökat med 1 178 799,90 SEK...